Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandeep Narpala

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Nature Communications|June 3, 2025
Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody responseKenta Matsuda, Mitra Harrison, Eleanor Wettstein, et al.
Cell Reports|April 27, 2017
Quantification of the Impact of the HIV-1-Glycan Shield on Antibody ElicitationTongqing Zhou, Nicole A Doria-Rose, Cheng Cheng, et al.
Eclinicalmedicine|July 5, 2022
Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trialKatherine V Houser, Martin R Gaudinski, Myra Happe, et al.
Nature Medicine|February 4, 2022
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trialKatherine V Houser, Grace L Chen, Cristina Carter, et al.
Nature Medicine|April 12, 2022
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trialJoseph P Casazza, Evan M Cale, Sandeep Narpala, et al.
Nature Communications|November 12, 2024
Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trialLindsay N Carpp, Ollivier Hyrien, Youyi Fong, et al.
Medrxiv : the Preprint Server for Health Sciences|April 20, 2022
Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical TrialYouyi Fong, Adrian B McDermott, David Benkeser, et al.
Nature Microbiology|November 10, 2022
Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trialYouyi Fong, Adrian B McDermott, David Benkeser, et al.
Iscience|November 10, 2025
Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trialAlex Luedtke, Youyi Fong, Lars van der Laan, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Nature Communications|June 3, 2025
Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody responseKenta Matsuda, Mitra Harrison, Eleanor Wettstein, et al.
Cell Reports|April 27, 2017
Quantification of the Impact of the HIV-1-Glycan Shield on Antibody ElicitationTongqing Zhou, Nicole A Doria-Rose, Cheng Cheng, et al.
Eclinicalmedicine|July 5, 2022
Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trialKatherine V Houser, Martin R Gaudinski, Myra Happe, et al.
Nature Medicine|February 4, 2022
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trialKatherine V Houser, Grace L Chen, Cristina Carter, et al.
Nature Medicine|April 12, 2022
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trialJoseph P Casazza, Evan M Cale, Sandeep Narpala, et al.
Nature Communications|November 12, 2024
Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trialLindsay N Carpp, Ollivier Hyrien, Youyi Fong, et al.
Medrxiv : the Preprint Server for Health Sciences|April 20, 2022
Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical TrialYouyi Fong, Adrian B McDermott, David Benkeser, et al.
Nature Microbiology|November 10, 2022
Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trialYouyi Fong, Adrian B McDermott, David Benkeser, et al.
Iscience|November 10, 2025
Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trialAlex Luedtke, Youyi Fong, Lars van der Laan, et al.
Pageof 5